1. Early F-18-FDHT PET/CT as a predictor of treatment response in mCRPC treated with enzalutamide.

   Hoving, H., Palthe, S., Vallinga, M., Dost, R., Gietema, J. A., Antunes, I., De Vries, E. F. J., Glaudemans, A. & de Jong, I. J., 1-Mar-2019, In : Journal of Clinical Oncology. 37, 7_Suppl, p. 232-232 1 p.

   Research output: Contribution to journal › Meeting Abstract › Academic

2. F-18-FDHT PET/CT as a predictor of treatment response in mCRPC treated with enzalutamide

   Hoving, H. D., Palthe, S., Dost, R. J., Vallinga, M. S., Gietema, J. A., Antunes, I. F., de Vries, E. F. J., Glaudemans, A. W. J. M. & de Jong, I. J., Oct-2018, In : European Journal of Nuclear Medicine and Molecular Imaging. 45, p. S152 1 p.

   Research output: Contribution to journal › Meeting Abstract › Academic

3. EpCAM Expression in Lymph Node and Bone Metastases of Prostate Carcinoma: A Pilot Study

   Campos, A. K., Hoving, H. D., Rosati, S., van Leenders, G. J. L. H. & de Jong, I. J., 29-Sep-2016, In : International Journal of Molecular Sciences. 17, 10, 9 p., 1650.

   Research output: Contribution to journal › Article › Academic › peer-review

4. PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after Radiotherapy

   Rybalov, M., Ananias, H. J. K., Hoving, H. D., van der Poel, H. G., Rosati, S. & de Jong, I. J., 10-Apr-2014, In : International Journal of Molecular Sciences. 15, 4, p. 6046-6061 16 p.

   Research output: Contribution to journal › Article › Academic › peer-review

5. CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model

   Domanska, U. M., Boer, J. C., Timmer-Bosscha, H., van Vugt, M. A. T. M., Hoving, H. D., Kliphuis, N. M., Rosati, S., van der Poel, H. G., de Jong, I. J., de Vries, E. G. E. & Walenkamp, A. M. E., Oct-2014, In : Clinical & experimental metastasis. 31, 7, p. 829-839 11 p.

   Research output: Contribution to journal › Article › Academic › peer-review

View all (8) »